Since then, several other GLP-1RAs have been approved for type 2 diabetes management, available either for subcutaneous injection (exenatide, lixisenatide, liraglutide, dulaglutide, albiglutide, semaglutide), oral administration (semaglutide), or as fixed-dose combinations (liraglutide/insulin degludec, lixisenatide/insulin glargine) [56]. Here, INS is linked to type 2 diabetes mellitus.